Stock Analysis on Net
Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

Cash Flow Statement
Quarterly Data

Beginner level

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company’s balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Boston Scientific Corp., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel LibreOffice Calc
3 months ended: Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Cash provided by (used for) operating activities 269  (77) 692  502  292  350  19  501  (403) 193  684  452  297  (7) 466  (31) 421  116  329  408  60  (197)
Purchases of property, plant and equipment (68) (100) (186) (121) (91) (63) (106) (76) (74) (60) (79) (60) (68) (112) (167) (71) (78) (60) (85) (70) (46) (46)
Proceeds from sale of property, plant and equipment —  14  —  —  —  —  —  —  —  —  —  (1) 30  —  —  —  — 
Payments for acquisitions of businesses, net of cash acquired (2) —  (1) (3,618) (442) (321) (480) (550) (409) (9) (168) —  (392) —  (338) (70) —  —  (92) (1,579) (63) — 
Proceeds from royalty rights 22  23  52  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Payments for investments and acquisitions of certain technologies (27) (2) (11) (22) (87) (28) (23) (36) (8) (104) (42) (42) (19) (28) (27) (64) (23) (18) (54) (70) (137) (5)
Proceeds from divestiture of certain businesses 15  —  —  90  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Payments for settlements of hedge contracts —  —  95  (294) —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Proceeds from investments and collections of notes receivable —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  61  —  —  — 
Cash used for investing activities (59) (76) (49) (3,962) (620) (410) (595) (662) (491) (173) (289) (102) (479) (140) (532) (205) (102) (48) (170) (1,719) (246) (51)
Payment of contingent consideration and royalty rights previously established in purchase accounting (14) (76) —  (71) (57) (7) (3) (11) (5) —  (3) (12) —  (18) (30) —  (14) (21) (54) (15) —  (87)
Proceeds from royalty rights transfer —  —  256  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Payments on short-term borrowings (2,400) (300) —  —  —  (1,000) —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Proceeds from short-term borrowings, net of debt issuance costs 1,245  1,000  700  —  —  —  —  999  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Net increase (decrease) in commercial paper —  (714) (588) (662) 305  370  424  (875) 788  (316) (70) 240  1,013  —  —  —  —  —  —  —  —  — 
Payments on borrowings from credit facilities (1,440) (479) —  —  —  —  —  —  (569) —  —  —  (1,481) (735) (240) (290) —  (40) —  (170) (395) — 
Proceeds from borrowings on credit facilities 77  1,839  —  —  —  —  —  —  499  70  —  —  1,140  1,016  300  290  —  40  —  170  395  — 
Payments on long-term borrowings and debt extinguishment costs —  (1,000) (2,088) —  —  (1,472) —  —  —  (602) —  (400) (350) (250) —  —  (250) —  (150) —  (1,000) — 
Proceeds from long-term borrowings, net of debt issuance costs 1,683  —  986  2,000  —  4,243  (2) —  (1) 990  —  —  —  —  —  —  —  —  —  749  1,831  — 
Net proceeds from issuance of preferred stock in connection with public offering 975  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Net proceeds from issuance of common stock in connection with public offering 975  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Cash used to net share settle employee equity awards (1) (56) (1) (3) (1) (60) (2) (2) (2) (50) (1) (2) (1) (61) (5) (1) (57) (4) —  (1) (61)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans 42  11  50  53  40  16  38  35  11  33  35  46  27  17  27  16  54 
Cash provided by (used for) financing activities 1,105  256  (724) 1,314  256  2,127  425  151  726  130  (68) (139) 332  (15) 28  34  (217) (51) (191) 761  846  (94)
Effect of foreign exchange rates on cash (10) 12  (2) —  —  —  (4) (6) —  (3) (2) (3) (3)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents 1,316  93  (69) (2,148) (72) 2,067  (151) (14) (174) 151  328  213  150  (161) (41) (201) 100  19  (31) (553) 661  (345)

Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-07-30), 10-Q (filing date: 2019-04-29), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-10-29), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-05-01), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-03), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-03), 10-Q (filing date: 2016-05-04), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-06).

Cash flow statement item Description The company
Cash provided by (used for) operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Boston Scientific Corp.’s cash provided by (used for) operating activities decreased from Q4 2019 to Q1 2020 but then slightly increased from Q1 2020 to Q2 2020.
Cash used for investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Boston Scientific Corp.’s cash used for investing activities decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 not reaching Q4 2019 level.
Cash provided by (used for) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Boston Scientific Corp.’s cash provided by (used for) financing activities increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.